Inhibition of Platelet Absorption

a platelet absorption and inhibition technology, applied in the field of electrospun coatings, can solve the problems of reducing the potential for activating platelets to be removed, reducing the flow and thrombosis of the graft, and vascular grafting synthesized grafts

Inactive Publication Date: 2018-11-15
XELTIS AG
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018]In still another variation of the embodiment, the tubular structure has an outer wall reinforced by a braided structure, polymer strands, compounds or a combination thereof to provide resistance to prevent collapse of the cardiovascular graft.

Problems solved by technology

The predominantly observed failure mode of synthetic vascular grafts in clinical setting is progressive intimal hyperplasia at venous (outflow) anastomosis leading to reduced flow and thrombosis of the graft.
This is due to circulating platelets remaining in the vicinity of the growing thrombus for a longer time, as well as reduced shear stresses on adhered platelets due to reduced flow, reducing the potential for activated platelets to be removed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibition of Platelet Absorption
  • Inhibition of Platelet Absorption
  • Inhibition of Platelet Absorption

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031]The invention relates to a cardiovascular graft with highly reduced thrombogenicity by having an electrospun mesh produced from supramolecular polymers (SP). Preferably, the vascular graft is a non-woven mesh and / or large diameter fibers. The invention also relates to a method to produce such grafts via electrospinning. The invention further relates to the implantation of the vascular graft into the human body to allow vascular bypass / reconstruction, or repeated venous access for dialysis treatment, as well as other disorders of small-diameter blood vessels.

[0032]With the design of the cardiovascular graft, as defined infra, the inventors have demonstrated and describe herein unexpected platelet behavior on vascular grafts produced from SP. Platelet activation and adhesion were observed without significant spreading, aggregation or philopodia formation, in stark contrast with widely available “biocompatible” materials such as PTFE. Such outcomes prove that the material is idea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

A cardiovascular graft is provided with highly reduced thrombogenicity. The cardiovascular graft is an electrospun non-woven mesh produced from supramolecular polymers with large diameter fibers. The cardiovascular graft can be implemented as a vascular graft into the human body to allow vascular bypass/reconstruction, or repeated venous access for dialysis treatment, as well as other disorders of small-diameter blood vessels.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority from U.S. Provisional Patent Application 62 / 479,554 filed Mar. 31, 2017, which is incorporated herein by reference. This application claims priority from U.S. Provisional Patent Application 62 / 611,431 filed Dec. 28, 2017, which is incorporated herein by reference.FIELD OF THE INVENTION[0002]This invention relates to electrospun coatings, grafts or materials to inhibit thrombogenic effects.BACKGROUND OF THE INVENTION[0003]Vascular disease involving blood vessels with a luminal diameter of 6 mm or less constitutes the majority of disease cases requiring clinical intervention. In many of these cases the preferred intervention is vascular reconstruction or bypass surgery, utilizing either autologous vessels harvested from elsewhere in the patient or synthetic vascular grafts. Such synthetic grafts are available in a range of dimensions and configurations and generally have a small set of medical polymers such ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F2/00A61M1/36A61F2/06A61L27/18
CPCA61F2/0077A61M1/3655A61F2/06A61L27/18A61F2250/0067A61F2210/0004A61F2240/001A61F2002/0091A61F2002/0081A61L33/0005A61L33/0047A61L33/007A61L33/06A61L31/04A61L31/14A61L31/146A61L31/148A61L31/16A61L2300/42A61L2300/432
Inventor BURKE, LUKE DAVIDCOX, MARTIJN ANTONIUS JOHANNESSERRERO, AURELIE
Owner XELTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap